Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
Jordi RiberaIsabel GranadaMireia MorgadesTeresa GonzálezJuana CiudadEsperanza SuchMaría-José CalasanzSantiago MercadalRosa CollJosé González-CamposMar TormoIrene García-CadenasCristina GilMarta CerveraPere BarbaDolors CostaRosa AyalaArancha BermúdezAlberto OrfaoJosep-Maria Riberanull nullPublished in: British journal of haematology (2021)
The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).
Keyphrases
- stem cell transplantation
- end stage renal disease
- newly diagnosed
- transcription factor
- ejection fraction
- chronic kidney disease
- young adults
- mental health
- high dose
- emergency department
- peritoneal dialysis
- rheumatoid arthritis
- bone marrow
- patient reported outcomes
- intensive care unit
- low dose
- systemic lupus erythematosus
- childhood cancer
- mesenchymal stem cells
- single cell
- respiratory failure
- free survival
- smoking cessation
- acute respiratory distress syndrome
- drug induced
- disease activity
- aortic dissection
- replacement therapy